US 9611322
Fusions of antibodies to CD38 and attenuated interferon alpha
granted A61KA61K38/00A61K47/642
Quick answer
US patent 9611322 (Fusions of antibodies to CD38 and attenuated interferon alpha) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Grant date
- Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K38/00, A61K47/642, A61P, A61P35/00